PlusVitech
PlusVitech develops cancer treatments that aim to provide safe, non-toxic, orally administered options for patients, including those with limited alternatives. The company uses drug repositioning—most notably its PVT-REMOVE program—with clinical evidence of complete remissions and a growing clinical trial program, including a Phase 2 lung cancer study. Its approach combines small molecules, monoclonal antibodies, diagnostic techniques such as liquid biopsy, and clinical data models, and the firm is developing an AI system called Amara for precision medicine. PlusVitech holds around 20 international patents covering its therapies and a complementary diagnostic test to personalize treatment. The company operates as a biotechnology/pharmaceutical developer focused on clinical advancement, licensing, and broader access to oncology therapeutics.
PlusVitech
PlusVitech develops cancer treatments that aim to provide safe, non-toxic, orally administered options for patients, including those with limited alternatives. The company uses drug repositioning—most notably its PVT-REMOVE program—with clinical evidence of complete remissions and a growing clinical trial program, including a Phase 2 lung cancer study. Its approach combines small molecules, monoclonal antibodies, diagnostic techniques such as liquid biopsy, and clinical data models, and the firm is developing an AI system called Amara for precision medicine. PlusVitech holds around 20 international patents covering its therapies and a complementary diagnostic test to personalize treatment. The company operates as a biotechnology/pharmaceutical developer focused on clinical advancement, licensing, and broader access to oncology therapeutics.